Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Erkelenz – page 11

1 570 clinical trials in Erkelenz, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Erkelenz at a glance
1 570
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 570 trials in Erkelenz

Open in trial search

A Study of ABBV-706 to Assess Safety and Efficacy Compared with Standard Drug Combination in Adults with Relapsed or Refractory Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Durvalumab plus drug combination as total neoadjuvant therapy for patients with resectable gastroesophageal adenocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Phase 1/2 Study of Oral TRI-611 in Adults With Advanced ALK‑Positive Non‑Small Cell Lung Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:TRI-611
  • Sponsor:Triana Biomedicines Inc.

Safety and Efficacy of BMS-986528 with Tocilizumab in Patients with Refractory Rheumatoid Arthritis: A Phase 1/2a Open‑Label Study

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:BI 3821001
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Effectiveness and Safety of INTESTIFIX in Removing Vancomycin‑Resistant Enterococci Colonization in Immunocompromised Patients – drug combination

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:Fraunhofer Institute For Translational Medicine And Pharmacology ITMP

HIV infection

Recruiting

Switching to Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults with HIV-1: A Phase 3 Randomized Study

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abacavir
  • Sponsor:Gilead Sciences Inc.

HIV infection

Recruiting

Switching to lenacapavir-based drug combination vs cabotegravir-based drug combination in virologically suppressed adults with HIV-1

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cabotegravir
  • Sponsor:Gilead Sciences Inc.

Breast neoplasm

Recruiting

Study of LY3484356 (imlunestrant) with Tamoxifen Citrate and Goserelin Acetate in Premenopausal Women with ER‑Positive, HER2‑Negative Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Goserelin Acetate
  • Sponsor:Eli Lilly & Co.

Cevostamab plus pomalidomide and dexamethasone in patients with multiple myeloma previously treated with BCMA‑targeted CAR T‑cell therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cevostamab
  • Sponsor:F. Hoffmann-La Roche AG

Efficacy and safety of votoplam in adults with Huntington’s disease: a randomized, double‑blind, placebo‑controlled Phase 3 trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Votoplam
  • Sponsor:Novartis Pharma AG

Study of precemtabart tocentecan alone or in drug combination versus standard therapy in previously treated metastatic colorectal cancer patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Healthcare KGaA

COVID-19

Recruiting

Study of nirmatrelvir and remdesivir to achieve viral clearance in immunocompromised patients with persistent COVID-19

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nirmatrelvir
  • Sponsor:Goethe University Frankfurt

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Erkelenz

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on triple-negative breast cancer evaluating the effectiveness of combining immunotherapy with traditional chemotherapy treatments. Studies aim to improve patient outcomes through personalized therapeutic approaches.

  • Triple-Negative Breast Cancer Treatment
  • Immunotherapy Integration
  • Event-Free Survival Assessment

Research explores novel combination therapies to enhance treatment efficacy.

02 Hormone Receptor Research

Studies examining personalized treatment strategies for HR+/HER2- breast cancer patients, comparing endocrine therapy combinations with standard chemotherapy approaches. Focus on long-term survival outcomes.

  • Endocrine Therapy Enhancement
  • Disease-Free Survival Analysis
  • Personalized Treatment Protocols

Investigation of targeted therapies to improve treatment effectiveness.

03 Advanced Treatment Studies

Research evaluating novel therapeutic approaches for HER2-negative breast cancer patients, particularly those at high risk of relapse after standard treatments. Focus on comparing innovative targeted therapies with conventional approaches.

  • High-Risk Patient Treatment
  • Relapse Prevention Strategies
  • Comparative Treatment Efficacy

Development of targeted solutions for challenging breast cancer cases.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.